3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are among the most prescribed medications in the United States. Statins act on the rate-limiting step in cholesterol biosynthesis (the conversion of HMG-CoA to mevalonate) and are effective in treating dyslipidemia. However, statins decrease other downstream products of the mevalonate pathway, and it is via these pathways that statins may affect inflammation, nitric oxide synthesis, the coagulation cascade, and other processes. Through these pleiotropic effects, statins may have an effect on neurologic diseases, including ischemic and hemorrhagic stroke, Alzheimer disease, Parkinson disease, and multiple sclerosis. This article reviews the basic biochemistry of statins as it relates to these pleiotropic effects, the potential role of statins in several neurologic disorders, and the results of clinical trials performed for several of these conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“3-Hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, act on the rate-limiting step in the pathway by which HMG-CoA is converted to mevalonate.(1) Through their effect on this pathway (Figure), as well as an increase in low-density lipoprotein cholesterol (LDL-C) receptors and up…”
BackgroundHigh-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke
Chen, J., Zhang, Z. G., Li, Y., Wang, Y., Wang, L., Jiang, H., Zhang, C., Lu, M., Katakowski, M., Feldkamp, C. S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10555 · Cited by 538 · cited 1×
“Statins have also been shown to reduce inflammation and to increase angiogenesis, synaptogenesis, and neurogenesis when started up to 24 hours after stroke.(19) In addition, the reduction of membrane cholesterol synthesis in neurons may render them more resistant to glutamate N-methyl-D-aspartate receptor–mediated exc…”
BackgroundRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438 · cited 1×
“The Lipitor’s Effect in Alzheimer Dementia study enrolled 640 subjects already taking donepezil hydrochloride (10 mg) and randomized subjects in a doubleblind fashion to receive atorvastatin (80 mg) vs placebo with a baseline LDL-C of 95 to 195 mg/dL.(45) The investigators failed to find a benefit in cognition (as mea…”
MethodPravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291
Statin Therapy Inhibits Remyelination in the Central Nervous System
Miron, V. E., Zehntner, S. P., Kuhlmann, T., Ludwin, S. K., Owens, T., Kennedy, T. E., Bedell, B. J., & Antel, J. P. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080947 · Cited by 141
Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo
Klopfleisch, S., Merkler, D., Schmitz, M., Klöppner, S., Schedensack, M., Jeserich, G., Althaus, H. H., & Brück, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2765-08.2008 · Cited by 97
Cited by
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
HDL in innate and adaptive immunity
Catapano, A. L., Pirillo, A., Bonacina, F., & Norata, G. D. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu150 · Cited by 299
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
“Statins are a group of drugs that lower the production of cholesterol by specifically inhibiting HMG-CoA reductase activity, a rate-limiting step of the mevalonate pathway [87].”
BackgroundNew drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Gougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., Yekehtaz, H., & Akhondzadeh, S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578160 · Cited by 77
“There are a growing number of trials showing the benefits of statins in different neuropsychiatric disorders including neurodegenerative and neuro-inflammatory diseases (Corrao et al., 2013; Willey and Elkind, 2010).”
Background
Metadata
- Authors
- Willey, J. Z., & Elkind, M. S. V.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-09-01
- Volume
- 67
- Issue
- 9
- Pages
- 1062-7
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2158402891
- Cited by
- 102
- References
- 8
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases. https://app.cochat.ai/papers/10.1001/archneurol.2010.199
- The paper
- Willey, J. Z., & Elkind, M. S. V. (2010). 3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases. Archives of Neurology. https://doi.org/10.1001/archneurol.2010.199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.